Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

313.51 +1.01 (+0.32%)
Streaming Delayed Price Updated: 9:35 AM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 59,711
Open 313.66
Bid (Size) 312.35 (1)
Ask (Size) 314.39 (2)
Prev. Close 312.50
Today's Range 312.18 - 314.43
52wk Range 253.30 - 346.85
Shares Outstanding N/A
Dividend Yield 2.87%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amgen's Options: A Look at What the Big Money is Thinking
Via Benzinga
Is Eli Lilly Stock a Buy?
Via The Motley Fool

Performance

YTD
+20.92%
+20.92%
1 Month
+6.35%
+6.35%
3 Month
+14.67%
+14.67%
6 Month
-4.99%
-4.99%
1 Year
+13.37%
+13.37%

More News

Read More
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Via Benzinga
3 Magnificent Growth Stocks to Buy in March
Via The Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Via The Motley Fool
2 Reasons to Watch AMGN and 1 to Stay Cautious
Via StockStory
Topics Stocks
Exposures US Equities
Assessing Amgen: Insights From 9 Financial Analysts
Via Benzinga
Behind the Scenes of Amgen's Latest Options Trends
Via Benzinga
Looking Into Amgen's Recent Short Interest
Via Benzinga
Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials
Via Benzinga
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis
Via Benzinga
Bitcoin, Magnificent 7 Lose Safe-Haven Status In 2025 As China ETFs, Dow Stocks Outperform
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Amgen Unusual Options Activity For February 12
Via Benzinga
This Could Be the Best GLP-1 Stock to Buy in 2025
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Synchronicity: Denying The Unexplainable
Via Talk Markets
Topics Stocks / Equities
Large Cap Biopharmaceutical Metrics And Performance Q1 2025
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Gilead Sciences (GILD) Q4 Earnings: What To Expect
Via StockStory
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
Via The Motley Fool
3 Fabulous Dividend Stocks to Buy in February
Via The Motley Fool
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
Via StockStory
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Via Stocktwits
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.